Researchers conducted a 32,000-participant, randomized controlled clinical trial, called FIM12. Researchers performed a cost-utility analysis from a Canadian healthcare perspective. Additionally, they mapped clinical illness data from the trial to quality-of-life data.
Researchers found that average per-participant medical costs were $47 lower for the high-dose inactivated influenza vaccine group. Societal costs were $60 lower in the same group.
Hospitalizations accounted for 91 percent of the total cost and were less frequent in the high-dose inactivated influenza vaccine group. In Canada, high-dose inactivated influenza vaccine is expected to be a less costly and more effective alternative to standard-dose vaccine, driven by a reduction in hospitalizations.
More articles on healthcare quality:
Bloodstream infection clusters across 3 states may be associated with central lines
Readmissions past 7 days may be out of hospitals’ control, study finds
Lower heart rates reduce risk of death among septic shock patients: 4 insights
At the Becker's 11th Annual IT + Revenue Cycle Conference: The Future of AI & Digital Health, taking place September 14–17 in Chicago, healthcare executives and digital leaders from across the country will come together to explore how AI, interoperability, cybersecurity, and revenue cycle innovation are transforming care delivery, strengthening financial performance, and driving the next era of digital health. Apply for complimentary registration now.